Ovid Therapeutics Inc. (NASDAQ:OVID)
| Market Cap | $415.21M+57.1% |
| Revenue (ttm) | $1.45M-78.0% |
| Net Income | -$43.11M-18.7% |
| EPS | -$0.18+64.4% |
| Shares Out | 188.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,833,192 |
| Open | $2.26 |
| Previous Close | $2.34 |
| Day's Range | $2.17 - $2.33 |
| 52-Week Range | $1.26 - $3.11 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | $6.25(+184.09%) |
| Earnings Date | Mar 15, 2027 |
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating OVID in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 15, 2027Earnings report
$OVID stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OVID holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OVID's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OVID Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OVID Revenue by Segment
| OV329 | $6.56M | 47.98% |
| OV4071 | $3.75M | 27.42% |
| Legal and professional fees | $2.08M | 15.23% |
| KCC2 library | $692.00K | 5.06% |
| Other programs | $590.00K | 4.31% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OVID patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OVID from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OVID
| VTIVanguard Morningstar Total Stock Market ETF | $11.32M |
| IWMiShares Russell 2000 ETF | $9.92M |
| XBIState Street SPDR S&P Biotech ETF | $6.66M |
| VXFVanguard Extended Market ETF | $5.18M |
| IWNiShares Russell 2000 Value ETF | $3.15M |
| VTWOVanguard Russell 2000 ETF | $2.47M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from OVID’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 0.68% |
| IWC | iShares Micro-Cap ETF | 0.11% |
| XBI | State Street SPDR S&P Biotech ETF | 0.07% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.07% |
| AVNC | Avantis All International Core Equity ETF | 0.06% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.05% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.03% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.02% |
| PWS | Pacer WealthShield ETF | 0.02% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.01% |
| BSVO | EA Bridgeway Omni Small-Cap Value ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
